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Choosing an optimal first line antiret-
roviral therapy (ART) in resource-limited
settings (RLS) involves a careful balancing
act. On the one hand, we would want to
ensure that patients receive the most
efficacious therapy available. On the other
hand, the most efficacious regimens may
be too costly for countries afflicted by the
dual burdens of very high HIV prevalence
and of resource scarcity. This dilemma is
compounded by the recent emergence of
good quality evidence to start ART earlier
(i.e., at higher CD4 counts), which can
improve life expectancy [1], reduce the
risk of tuberculosis acquisition [1], and
reduce the transmission of HIV [2]. These
considerations will mean that about 9
million extra people will need to be placed
on ART by 2015 [3]—all in the context of
a decline in global funding for AIDS
during 2009 and 2010 [3].
The World Health Organization (WHO)
has thus advised that countries should
consider a number of factors in addition
to clinical efficacy when considering choice
of ART. These include in-country ART
costs, numbers of current and future
individuals needing to start ART, and the
country’s national prevalence of chronic
hepatitis B, tuberculosis, and anemia [4].
PEARLS Contributions
In a new study published in this week’s
PLoS Medicine, Thomas Campbell and
colleagues compared the efficacy and
safety of three ART regimens for treat-
ment naı¨ve patients in the Prospective
Evaluation of Antiretroviral Therapy in
Resource-Limited Settings (PEARLS) trial
[5]. They conducted a randomized con-
trolled trial to compare the efficacy and
safety of open-label ART with efavirenz
plus lamivudine-zidovudine (EFV+3TC-
ZDV), atazanavir plus didanosine-EC plus
emtricitabine (ATV+DDI+FTC), or efa-
virenz plus emtricitabine-tenofovir-DF
(EFV+FTC-TDF). Of note, their study
population was considerably more repre-
sentative of the global population of
people with HIV than many other studies.
The study population of 1,571 individuals
with HIV-1 was drawn from nine coun-
tries (including eight low- and middle-
income countries) in four continents.
Forty-seven percent were women.
The trial found that ATV+DDI+FTC
was inferior to EFV+3TC-ZDV in terms
of treatment efficacy (21% and 15%
treatment failures, respectively). EFV+
3TC-ZDV and EFV+FTC-TDF were
equally efficacious (19% and 18% treat-
ment failures, respectively). This is in
contrast to the only other randomized
controlled trial to have evaluated the
relative efficacy of these two regimens
(GS-01-934), which found EFV+FTC-
TDF to be more efficacious than
EFV+3TC-ZDV [6]. In common with
other trials, PEARLS found that the
EFV+ZDV-3TC regimen was associated
with more side effects requiring drug
substitution than the EFV+FTC-TDF
regimen.
How do we explain the discrepant
findings between PEARLS and GS-01-
934? The authors of PEARLS provide a
plausible explanation relating to differenc-
es in how the primary efficacy endpoints
were defined. GS-01-934 used as primary
endpoint the US Food and Drug Admin-
istration (FDA) time to loss of virologic
response (TLOVR). This includes all
antiretroviral (ARV) substitutions as end-
points (failures). The ZDV containing arm
had more adverse events than the TDF
arm (22 versus 9), and this was the main
determinant of the difference in primary
endpoint between the two arms. Their
explanation is given further credence by a
reanalysis of PEARLS using the FDA-
recommended TLOVR as the primary
outcome. This transformed the PEARLS
outcomes to concur with those of GS-
01-934—the TDF regimen was superior.
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Campbell TB, Smeaton LM, Kumar-
asamy N, Flanigan T, Klingman KL,
et al. (2012) Efficacy and Safety of
Three Antiretroviral Regimens for
Initial Treatment of HIV-1: A Ran-
domized Clinical Trial in Diverse
Multinational Settings. PLoS Med
9(8): e1001290. doi:10.1371/journal.
pmed.10001290
Thomas Campbell and colleagues
report findings of a randomized trial
conducted in multiple countries
regarding the efficacy of antiretro-
viral regimens with simplified dos-
ing.
The Perspective section is for experts to discuss the
clinical practice or public health implications of a
published study that is freely available online.
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In our opinion, a cogent case can be
made that including protocol-pre-specified
drug substitutions in an efficacy endpoint
that is labeled as virological suppression is
misleading. Both the rates of virological
suppression and drug side effects are
important endpoints, but it is unhelpful
and misleading to conflate the two into
one category and then label this as
virological suppression. Of further note,
the analytical approach taken in GS-
01-934 favoured the commercial funder
of the trial, Gilead Sciences. Six of the 12
authors of GS-01-934 were employees of
Gilead, who manufacture TDF, and
according to the authors of GS-01-934,
‘‘the study was designed by and the data
were analyzed at Gilead Sciences’’ [6].
Practical Implications
The PEARLS study provides further
evidence to back up the first two of four
ART regimens listed by the WHO guide-
lines as acceptable first line ART regi-
mens: AZT +3TC+EFV, TDF+3TC (or
FTC)+EFV, AZT+3TC+NVP, and TDF+
3TC (or FTC)+NVP [4].
PEARLS confirms the widely held view
that TDF/FTC/EFV is an excellent first
line ART regimen for use in RLS [7]. Its
advantages include daily dosing, availabil-
ity in a fixed dose combination, compat-
ibility with tuberculosis treatment, effect
on hepatitis B, low rates of side effects, and
more recently the fact that the cheapest
generic price for TDF is lower than that of
the equivalent for ZDV [3]. The ability of
RLS to access the cheapest ARVs varies
dramatically [3,8]. The evidence from
PEARLS that ZDV has equivalent viro-
logical suppression to TDF could be used
by these countries and others to further
link ZDV and TDF in competitive price
reductions.
One of the most useful contributions
that PEARLS makes to our knowledge of
ART is the lack of heterogeneity of
efficacy or toxicity of ART according to
country, continent, race, and/or ethnicity.
There have been numerous concerns
raised in the literature that there may be
increased risks of drug toxicity from
particular ARVs in specific populations.
It has been argued that there is a risk that
both TDF [9] and EFV [10] would have
greater side effect rates in African popu-
lations. Reassuringly, PEARLS found no
evidence of differential efficacy or toxicity
by country, continent, race, or ethnicity.
Future Studies
Nevertheless, there are a number of
limitations with the PEARLS trial that
point the way for future research. One of
these is the choice of protease inhibitor
(PI)-based ART—unboosted ATV/DDI/
FTC. A number of trials have shown the
superiority of boosted- over unboosted-
ATV, and this is now widely regarded as
best practice [11]. A further problem is the
inclusion of DDI, a drug whose toxicity
and complexity in dosing has led to its
exclusion from numerous guidelines for
first line ART. It was thus not surprising
that this regimen was less efficacious than
EFV+3TC/ZDV. Given the suboptimal
nature of this regimen, one certainly
cannot generalize the findings to other
PI-based ART. PI-based ART may be a
good option for first line ART in RLS in
persons who have been exposed to ARVs
in the form of the prevention of mother-
to-child transmission or pre-exposure pro-
phylaxis [12]. Other first line regimens in
need of further research in RLS are
regimens including nevirapine 400 mg
daily and rilpivirine (which has less
neuropsychiatric side effects than EFV,
and could possibly be produced for as little
as US$10 per patient per year but is
somewhat less effective in patients with
high baseline viral loads [3]). New ARVs
that may become options for the future
include an alternative pro-drug version of
tenofovir, GS-7340, which requires a
lower dose and could be considerably
cheaper than TDF [13]. PEARLS has
provided policy makers and clinicians in
RLS with reassurance of the equivalence,
as far as virological suppression is con-
cerned, of EFV+3TC-ZDV and EFV+
FTC-TDF. For the reasons mentioned
above, TDF containing ART will remain
the optimal first line ART in RLS.
Unfortunately, we remain a long way
from ensuring that all ART-requiring
patients in RLS receive optimal ART
rather than more toxic regimens, or no
ART at all.
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